Physician profile
Eric L Smith
NPI 1134233745
$10,255.18
in general payments reported to CMS, 2019-2025
26 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $805 · 2021: $1,518 · 2022: $1,190 · 2023: $2,050 · 2024: $1,863 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,765 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,765.47 |
| Education | $248.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,426.29 | 2020-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $1,046.31 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,022.05 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $882.20 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $861.61 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $740.31 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $722.16 | 2019-2025 | Trintellix |
| Abbvie INC. | $670.81 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $667.84 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $333.68 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $304.18 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $251.95 | 2023-2024 | Quviviq |
| Allergan, INC. | $235.25 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $208.99 | 2020-2023 | Belsomra, Verquvo |
| Neurocrine Biosciences, INC. | $183.27 | 2021-2025 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $156.10 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $135.18 | 2023 | Dyanavel Xr, Quillichew Er, Quillivant |
| Almatica Pharma LLC | $125.32 | 2024 | Loreev Xr |
| Baxter Healthcare | $110.43 | 2025 | Perclot |
| Corium, LLC | $42.22 | 2022-2025 | Azstarys |
| Shire North American Group INC | $36.88 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.76 | 2022-2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $19.59 | 2022 | |
| Lilly USA, LLC | $16.44 | 2022 | |
| Eisai INC. | $15.99 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.